Cargando…
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as ‘Myeloproliferative Diseases’ and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential...
Autores principales: | de Freitas, Renata Mendes, da Costa Maranduba, Carlos Magno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685044/ https://www.ncbi.nlm.nih.gov/pubmed/26408371 http://dx.doi.org/10.1016/j.bjhh.2014.10.001 |
Ejemplares similares
-
The JAK2 gene as a protagonist in chronic
myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013) -
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015) -
JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms
por: Torres, Dania G., et al.
Publicado: (2022) -
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018) -
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)